Find verified Rimonabant API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Rimonabant for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Rimonabant API.
Alternate Names: Acomplia, Zimulti, Rimoslim
CAS No: 168273-06-1
PubChem CID: 104850
Mol Formula: C22H21Cl3N4O
Mol Weight: 463.8 g/mol
IUPAC Name: 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
API Description: Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
